Results 171 to 180 of about 823,777 (226)

Aptamer-Based Heterobifunctional Targeted Degraders in Disease Treatment. [PDF]

Molecules
Liang X, Du M, Wang J, Lei X, Tian Y, Zhang X.   +5 more
europepmc   +1 more source

Editorial: Targeting the Wnt/β-catenin signaling pathway in cancer, volume II. [PDF]

Front Oncol
Patergnani S, Buchsbaum DJ, Piazza GA, Zhou G.   +3 more
europepmc   +1 more source

Research Trends and Emerging Frontiers in Proteolysis Targeting Chimeras (PROTACs): A Bibliometric Analysis of 2630 Publications (2001-2025). [PDF]

Pharmaceuticals (Basel)
Su G, Wang Y, Yao L.
europepmc   +1 more source

Targeting drug resistance in breast cancer: a dual-perspective landscape analysis of PROTACs from bench to bedside. [PDF]

Breast Cancer Res
Yang Y, Lin Y.
europepmc   +1 more source

Harnessing p53 for Proximity Killing. [PDF]

Int J Mol Sci
Zawacka JE.
europepmc   +1 more source

Structure-guided engineering of an aptamer-PROTAC for targeted degradation of vaccinia-related kinase 1. [PDF]

Chem Sci
Yun Y, Gao Y, Shi Y, Zhang J.
europepmc   +1 more source

Proteolysis targeting chimeras (PROTAC) for targeting Alzheimer’s disease

Discover Neuroscience
Archna Singh, Anjna Rani, Avijit Mazumder   +2 more
openaire   +1 more source

Induced proximity-based therapeutics for advanced prostate cancer. [PDF]

NPJ Drug Discov
Ching J, Chau CH, Figg WD.
europepmc   +1 more source

Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery. [PDF]

Angew Chem Int Ed Engl
Venne JL, Krajcovicova S, Davies G, Bolt H, Revell J, Spring DR.   +5 more
europepmc   +1 more source

Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome <i>c</i>-Apaf-1 axis in cancer therapy. [PDF]

Oncoscience
Jemmerson R.
europepmc   +1 more source